Lates News

A spokesperson for Regeneron Pharmaceuticals company stated that the company has rejected a new acquisition offer from the genetic testing company 23andMe for more than $256 million. During the bankruptcy auction, a non-profit organization controlled by 23andMe co-founder Anne Wojcicki made a $305 million bid that exceeded Regeneron's offer, meaning that Wojcicki will regain control of 23andMe.